Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors

Malignant rhabdoid tumors (MRTs) are rare and highly aggressive pediatric cancers with no standard of care. MRTs are characterized by loss of SMARCB1, which results in upregulated expression of enhancer of zeste homolog 2 (EZH2), which is responsible for the methylation of lysine 27 of histone H3 (H...

Descripción completa

Detalles Bibliográficos
Autores principales: Shinohara, Haruka, Sawado, Rie, Nakagawa, Makoto, Hattori, Ayuna, Yamagata, Kazutsune, Tauchi, Kimiharu, Ito, Jumpei, Kuwahara, Yasumichi, Okuda, Tsukasa, Ogawa, Chitose, Kitabayashi, Issay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9529991/
https://www.ncbi.nlm.nih.gov/pubmed/36212776
http://dx.doi.org/10.1016/j.omto.2022.09.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9529991/
https://www.ncbi.nlm.nih.gov/pubmed/36212776
http://dx.doi.org/10.1016/j.omto.2022.09.006

Ejemplares similares